Genentech


Since 1994, MCS has been the agency of record for Genentech's lytics franchise, including Activase or t-PA, the first FDA-approved treatment for acute ischemic stroke within three hours of symptom onset; and TNKase, a single-bolus thrombolytic for the treatment of heart attack.

Genentech, Inc., a member of the Roche Group, is a leading biotechnology company that discovers, develops, manufactures, and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies.

For more information on Genentech, Inc., please visit the company's web site at www.gene.com.

Qforma


MCS provides corporate communication support for Qforma.

Qforma is an advanced analytics and predictive modeling company specializing in solutions for the pharmaceutical, biotech, and financial services industries. Its customized software applications utilize complex data flows to identify predictive patterns, quantify impacts and alert sales and marketing teams to evolving behaviors that affect product performance. Qforma is headquartered in Santa Fe, NM, with offices in Boston, MA and Princeton, NJ.

For more information on Qforma, please visit the company's web site www.qforma.com.

Merck


MCS provides U.S. and international communication support for a variety of products in the thrombosis and immunology franchises. They include: INTEGRILIN®, a GP IIb/IIIa inhibitor for acute coronary syndrome; vorapaxar, an investigational PAR-1 inhibitor for acute coronary syndrome; REMICADE®, an anti-TNF therapy for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn's disease, ulcerative colitis and psoriasis; and SIMPONI®, an anti-TNF therapy for rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.

Merck is the second-largest pharmaceutical company in the world and develops medicines, vaccines, biologic therapies, and consumer and animal products, with operations in more than 140 countries.

For more information on Merck, please visit the company's web site at www.merck.com.

CSL Behring


MCS provides communication support to CSL Behring for a variety of therapies for those with rare and serious disorders, including Berinert for the treatment of hereditary angioedema, Helixate for the treatment of hemophilia, Humate-P for the treatment of von Willebrand disease and Zemaira for the treatment of Alpha-1 Antitrypsin Deficiency.

CSL Behring is a global leader in the plasma protein biotherapeutics industry. Dedicated to improving the quality of life for patients throughout the world, CSL Behring provides safe and effective plasma-derived and recombinant products and offers patients a wide range of related services. The company's broad portfolio of life-saving therapeutics is used in the treatment of individuals with hemophilia and other bleeding disorders, immune deficiency disorders, and inherited emphysema; for the prevention of hemolytic diseases for the newborn; in cardiac surgery patients; and in shock and burn victims.

For more information on CSL Behring, please visit the company's web site at www.cslbehring.com.

MannKind Corporation


MCS provides communication support to MannKind for its investigational diabetes treatment, AFREZZA. MannKind Corporation focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFREZZA, which has completed phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes.

For more information on MannKind, please visit the company's web site at www.mannkindcorp.com.

Head and Neck Cancer Alliance


Annually, MCS publicizes the Head and Neck Cancer Alliance's annual Oral Head and Neck Cancer Awareness Week (OHANCAW) in April, which is designed to increase public awareness of head and neck cancer and encourage at-risk individuals to participate in nationwide free screenings for this life-threatening disease.

The mission of the Head and Neck Cancer Alliance is to provide support to head and neck cancer patients throughout the year; educate children and adults about the disease process, treatment, and prevention of head and neck cancer; and support ongoing research in head and neck oncology.

For more information please visit the following web sites: www.ohancaw.com or www.headandneck.org.

AETERNA ZENTARIS


MCS provides communication support to Aeterna Zentaris, a late-stage oncology drug development company currently investigating potential novel treatments for multiple myeloma, colorectal, prostate, bladder, ovarian and endometrial cancers. The company’s innovative approach is to tailor treatments to a patient’s specific condition and unmet medical needs. The Company’s deep pipeline is drawn from its own research and development library of 120,000 molecules, delivering constant and long-term access to state-of-the-art therapeutic options.

For more information on Aeterna Zentaris, please visit the company website www.aezsinc.com.

PDR NETWORK


MCS provides communications support to PDR Network LLC, the leading distributor of drug labeling information, product safety Alerts and REMS programs, including Physicians’ Desk Reference (PDR®), the most highly trusted and commonly used drug information reference available in the U.S; PDR.net; mobilePDR® and Health Care Notification Network (HCNN), the only service providing specialty-specific electronic delivery of FDA-approved safety Alerts to physicians. HCNN is governed by the not-for-profit iHealth Alliance.

For more information on PDR Network, please visit the company website PDR.net